MedTrace Logo

Enhancing Processing Speed and Executive Functioning in Depressed Older Adults With Computerized Cognitive Training

NCT04836533 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-03-28

No results posted yet for this study

Summary

The purpose of this research study is to determine how treatment response may change depending on how studies are designed, and if mobile cognitive training can be used to improve treatment response in depressed older adults.

Conditions

Interventions

OTHER

Experimental: Computerized Cognitive Training

Participants will complete 4 weeks of executive functioning / processing speed training through the BrainHQ platform on their personal computers.

DRUG

Experimental: Open-label antidepressant treatment

Participants will be assigned to open-label or placebo-controlled antidepressant treatment for 8 weeks.

OTHER

Active Comparator: Solitaire Training

Participants will complete 4 weeks of Solitaire training through the BrainHQ platform on their personal computers.

OTHER

Placebo Comparator: Placebo-controlled antidepressant treatment

Participants will be told they have a 50/50 chance of receiving a placebo or antidepressant.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • New York State Psychiatric Institute

    collaborator OTHER

  • Queens College, The City University of New York

    lead OTHER

Principal Investigators

  • Joel R Sneed, PhD · Queens College and NYSPI

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-31
Primary Completion
2023-01-31
Completion
2023-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04836533 on ClinicalTrials.gov